Targeting KRAS mutations in pancreatic cancer - Semantic Scholar
Our findings support TEAD inhibition as a therapeutic combination strategy to enhance the response rate and durability of direct KRAS inhibitor therapies.
Conquering oncogenic KRAS and its bypass mechanismsOne strategy to overcome resistance and to provide better disease control could be combination strategies to address the escape mechanisms in ... KRAS: Biology, Inhibition, and Mechanisms of Inhibitor ResistanceThese findings demonstrate the benefit of combining BI-3406 with a KRASG12Ci to treat KRASG12C- mutated tumors that have acquired resistance to ... Effective drug combinations targeting driver KRAS mutations in non ...Combinatorial treatment of the KRAS G12C cell line, MIA PaCa-2, with AMG 510 and Torin 1 resulted in the inhi- bition of phosphorylation of the ...
Autres Cours:
